Abatacept for the treatment of rheumatoid arthritis only after the failure of conventional disease-modifying anti-rheumatic drugs
Status: |
History
|
Expected date of issue: |
August 2011 |
Referral date: |
July 2010 |
Process: |
STA |
Notes:
Scoped within Batch 12
|
Topic area:
|
NICE project team
Executive Lead: |
Andrew Dillon
|
Technical Lead: |
Scott Goulden
|
Communications manager: |
Tonya Gillis
|
Project manager: |
Jeremy Powell
|
Provisional schedule
Closing date for invited submissions / evidence submission: |
19 November 2010 |
1st appraisal committee meeting: |
02 March 2011 |
2nd appraisal committee meeting |
04 May 2011 |
Consultees and commentators
Consultees |
Commentators (no right to submit or appeal) |
Manufacturers/sponsors
- Bristol-Myers Squibb (abatacept)
Patient/carer groups
- Arthritis Care
- National Rheumatoid Arthritis Society
Professional groups
- British Health Professionals in Rheumatology
- British Society for Rheumatology
- Primary Care Rheumatology Society
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
Others
- Department of Health
- Heart of Birmingham Teaching PCT
- NHS Telford and Wrekin
- Welsh Assembly Government
|
General
- British National Formulary
- Commissioning Support Appraisals Service
- Department of Health, Social Services and Public Safety for Northern Ireland
- Medicines and Healthcare products Regulatory Agency
- NHS Quality Improvement Scotland
Possible comparator manufacturer(s)
- Abbott Laboratories (adalimumab)
- Actavis (azathioprine, sulfasalazine, penicillamine) (removed – no confidentiality form)
- Alliance Pharmaceuticals (penicillamine) (removed – no confidentiality form)
- Almus Pharmaceuticals (sulfasalazine) (removed – no confidentiality form)
- Arrow Generics (azathioprine) (removed – no confidentiality form)
- Astellas (auranofin) (removed – no confidentiality form)
- AstraZeneca (chloroquine)
- Focus Pharmaceuticals (azathioprine) (removed – no confidentiality form)
- GlaxoSmithKline (azathioprine)
- IVAX Pharmaceuticals (azathioprine, sulfasalazine) (removed – no confidentiality form)
- Kent Pharmaceuticals (azathioprine, sulfasalazine, penicillamine) (removed – no confidentiality form)
- Mylan (azathioprine, sulfasalazine, penicillamine) (removed – no confidentiality form)
- Novartis (ciclosporin) (removed – no confidentiality form)
- Pfizer (sulfasalazine)
- Sandoz (azathioprine) (removed – no confidentiality form)
- Sanofi Aventis (hydroxychloroquine, leflunomide, sodium aurothiomalate)
- Schering-Plough (infliximab, golimumab)
- Teva UK (azathioprine, sulfasalazine, penicillamine)(removed – no confidentiality form)
- UCB Pharma (certolizumab pegol)
- Waymade Healthcare (sulfasalazine) (removed – no confidentiality form)
- Wyeth Pharmaceuticals (etanercept) (removed – no confidentiality form)
Relevant research groups
Evidence Review Group
- School of Health & Related Research Sheffield (ScHARR)
- National Institute for Health Research Health Technology Assessment Programme
Associated guideline groups
- National Clinical Guideline Centre
Associated public health groups
|
|
Key documents
This page was last updated: 30 July 2012